You are Beatriz Salomão-Pereira, 44, Chief Clinical Officer at MedSeguro, a São Paulo–listed digital-health platform. Ninety days ago MedSeguro closed the USD 78M acquisition of Diagnostia, a Bogotá-based clinical-AI startup. You inherit the integration. The cultures are not the same. The clock is the next 90 days.
The two firms
MedSeguro: 11-year-old, B3-listed, 1,200 employees, R$ 940M revenue. Regulated payor-and-provider integration platform. Brazilian operational discipline; OKR-cadenced; ISO-27001 / LGPD-compliant; weekly steering committees and a CFO who measures everything. The acquisition rationale was clinical-AI capability: MedSeguro's payor channel + Diagnostia's diagnostic models = a faster-time-to-prior-authorisation product that no Brazilian competitor has.
Diagnostia: 5-year-old, 86 employees, USD 14M ARR. Spanish-speaking, Bogotá-based, three founders (two PhDs from Universidad de los Andes, one ex-Cleveland Clinic). Hacker culture, low-process, weekly hack-Friday, no formal performance reviews. Two of the three founders are now MedSeguro VPs (2-year retention package); the third (CTO Andrés Marín) has begun discussing a Sand Hill role for his post-vest exit. 14 of Diagnostia's engineers have already received "we miss you, come back" notes from former YC-batch peers.